Medication info
Enpistar Tablets 40/5mg

Enpistar Tablets 40/5mg

Prescription medicationOral
Ingredient · strength
Telmisartan Powder 23.9%›167.36mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tablet
Manufacturer / importer
Daehan New Pharm Co., Ltd.
Appearance
This is a biconvex, oval double tablet that is white and light gray.
Packaging
30 tablets (10 tablets/PTPX3)
Approval status
Active

MFDS item code 201605822 · Approved 2016.09.30 · Insurance code 669906990

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as described below, a direct switch to this medicine may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. Patients taking telmisartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience (limited to this medicine 40/5 mg). ○ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: The usual amlodipine regimen is recommended for elderly patients, but caution should be exercised when increasing the dose (see section ‘3. Patients requiring careful administration’). In elderly patients aged 75 years or older, amlodipine clearance is reduced; therefore, start treatment at a low dose and increase the dose gradually.
Child dose
18 years of age or younger: The safety and efficacy of this medicine have not been established; therefore, its use is not recommended.

Ingredients

Manufacturer
Daehan New Pharm Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to effectively manage essential hypertension when blood pressure is not sufficiently controlled with telmisartan or amlodipine monotherapy.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as described below, a direct switch to this medicine may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. Patients taking telmisartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience (limited to this medicine 40/5 mg). ○ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: The usual amlodipine regimen is recommended for elderly patients, but caution should be exercised when increasing the dose (see section ‘3. Patients requiring careful administration’). In elderly patients aged 75 years or older, amlodipine clearance is reduced; therefore, start treatment at a low dose and increase the dose gradually.

Child dose

18 years of age or younger: The safety and efficacy of this medicine have not been established; therefore, its use is not recommended.

Precautions

This drug may pose serious risks to the fetus or newborn during pregnancy, especially in the second and third trimesters, and should not be taken by women who are pregnant or may become pregnant. People allergic to the active ingredients or similar substances, those with severe liver impairment, hypotension, or heart function issues should not take this medication. Patients with impaired liver or kidney function, the elderly, or patients with certain heart diseases should use this drug more cautiously and be monitored carefully according to a physician's instructions. When taking this medication, side effects such as dizziness, swelling, or hypotension may occur; if symptoms are severe, immediate consultation with a healthcare professional is necessary. It is crucial to monitor blood pressure and heart conditions regularly during treatment, especially since the medication can lower blood pressure too much or cause heart problems. This drug may interact with other medications, so inform your doctor or pharmacist about any current medications you are taking. Women who are pregnant or breastfeeding should not take this medication and should stop taking it immediately and consult a physician if pregnancy is planned or confirmed. The safety and efficacy have not been established for use in children, so its use is not recommended in this age group. In case of overdose, there is a risk of hypotension, dizziness, or heart function decline, requiring immediate medical attention.

Side effects

  • Dizziness
  • peripheral edema
  • syncope
  • upper respiratory tract infection
  • pharyngitis
  • sinusitis
  • urinary tract infection
  • cystitis
  • sepsis
  • anemia
Show 101 more
  • thrombocytopenia
  • eosinophilia
  • leukopenia
  • hypersensitivity
  • anaphylactic reaction
  • hyperkalemia
  • hypoglycemia
  • hyponatremia
  • hyperglycemia
  • depression
  • insomnia
  • mood changes
  • anxiety
  • confusion
  • drowsiness
  • headache
  • migraine
  • paresthesia
  • sensory loss
  • taste disturbances
  • tremors
  • extrapyramidal disorders
  • muscle rigidity
  • visual disturbances
  • diplopia
  • vertigo
  • tinnitus
  • palpitations
  • bradycardia
  • tachycardia
  • myocardial infarction
  • ventricular tachycardia
  • arrhythmia
  • atrial fibrillation
  • flushing
  • hypotension
  • orthostatic hypotension
  • cough
  • dyspnea
  • rhinitis
  • changes in bowel habits
  • diarrhea
  • constipation
  • abdominal pain
  • dyspepsia
  • nausea
  • vomiting
  • dry mouth
  • gingival hyperplasia
  • abdominal discomfort
  • pancreatitis
  • gastritis
  • liver dysfunction
  • liver disorder
  • hepatitis
  • jaundice
  • increased liver enzymes
  • pruritus
  • hyperhidrosis
  • rash
  • alopecia
  • purpura
  • skin discoloration
  • eczema
  • erythema
  • angioedema
  • toxic skin rash
  • drug rash
  • urticaria
  • erythema multiforme
  • exfoliative dermatitis
  • Stevens-Johnson syndrome
  • photosensitivity reaction
  • joint swelling
  • muscle cramps
  • arthralgia
  • myalgia
  • lumbar pain
  • limb pain
  • tendon pain
  • renal dysfunction
  • acute renal failure
  • urination disorders
  • polyuria
  • nocturia
  • erectile dysfunction
  • gynecomastia
  • edema
  • asthenia
  • fatigue
  • chest pain
  • malaise
  • influenza-like illness
  • increased liver enzymes
  • increased blood creatinine
  • weight gain
  • weight loss
  • increased blood uric acid
  • increased blood creatine phosphokinase
  • decreased hemoglobin
  • intestinal vascular edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a special container that does not allow light in. Additionally, it should be stored at room temperature, between 1 to 30 degrees Celsius, away from extremes of heat or cold to maintain effectiveness.

Appearance and packaging

Appearance

This is a biconvex, oval double tablet that is white and light gray.

Package unit

30 tablets (10 tablets/PTPX3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.